Chemocentryx, Inc.

Schering Corporation

Amgen Inc.

Daniel J Dairaghi

Thomas J Schall

Andrew M K Pennell

Brian E McMaster

Wei Yu Chen

Penglie Zhang

James Bradley Aggen

Subhabrata Bapi Sen

Sreenivas Punna

Yibin Zeng

Solomon Ungashe

Trevor T Charvat

Zheng Wei

Jimmie L Moore

John Jessen Wright

Jeff Jin

J J Kim Wright

Arindrajit Basak

Derek Hansen

Jay Patrick Powers

Manmohan Reddy Leleti

Venkat Reddy Mali

Ju Yang

Viengkham Malathong

Hiroko Tanaka

Christopher W Lange

Rebecca M Lui

Yandong Li

Dean R Dragoli

Michael R Hanley

Zhenhua Miao

Jennifa Gosling

Matthew J Walters

Joanne Tan

Qiang Wang

Antoni Krasinski

Jaroslaw Kalisiak

Wei W Wang

J J Wright

Atsushi Miyajima

Mark Penfold

Takahiko Hara

Jj Kim Wright

Subrabrata Sen

Julio Cesar Medina

Feng Xu

Lianfa Li

Dale John Talbot

Akihiko Yoshimura

Valeri Martichonok

Xuemei Wang

Andrew Mk Pennell

Tassie Collins

Hossen Mahmud

Jarek Kalisiak

Andrew MK Pennell

Arindrajit Badak

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

Heteroaryl sulfonamides and CCR2/CCR9

Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6: 

CCR6 compounds

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Substituted piperazines

Heteroaryl sulfonamides and CCR2

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

Bicyclic and bridged nitrogen heterocycles

Growing community of inventors

Palo Alto, CA, United States of America

Daniel J Dairaghi